AKT1 and plasma cell myeloma: Inhibition of PI3K/AKT signaling pathway by agents like LY294002 or rapamycin has been shown to reduce ABCG2 expression in human multiple myeloma (MM) cell lines, suggesting that PI3K/AKT signaling positively regulates ABCG2 levels [21].